Table 1—

Clinical characteristics of the study groups

PlaceboMetforminRosiglitazone
n10119
Sex (M/F)6/47/47/2
Age (years)57 ± 259 ± 257 ± 2
Before treatment
 BMI (kg/m2)31.5 ± 1.528.2 ± 1.129.2 ± 1.4
 FM (%)32.8 ± 3.131.9 ± 2.829.3 ± 3.4
 WHR (cm/cm)0.96 ± 0.020.95 ± 0.010.95 ± 0.01
 SBP (mmHg)147 ± 4142 ± 5148 ± 6
 DBP (mmHg)84 ± 384 ± 390 ± 3
 HR (bpm)63 ± 466 ± 370 ± 5
After treatment
 BMI (kg/m2)31.5 ± 1.527.1 ± 1.0*29.0 ± 1.4
 FM (%)32.8 ± 3.330.2 ± 2.628.6 ± 3.3
 SBP (mmHg)143 ± 5139 ± 5143 ± 3
 DBP (mmHg)84 ± 482 ± 385 ± 3
 HR (bpm)63 ± 366 ± 371 ± 3
  • Data are n or means ± SEM. DBP, diastolic blood pressure, FM, fat mass; HR, heart rate, SBP, systolic blood pressure, WHR, waist-to-hip ratio.

  • *

    * P < 0.002 vs. placebo and P = 0.01 vs. rosiglitazone;

  • P < 0.01 or less vs. baseline study (Student paired t test in individual groups).